Retraction: Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity (Proc Natl Acad Sci USA (2014) 111, (1939-1944) DOI: 10.1073/pnas.1317350111);Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 5, 2014, Pages 1939-1944

  Messer, William B ^a   De Alwis, Ruklanthi ^b   Yount, Boyd L ^c   Royal, Scott R ^c   Huynh, Jeremy P ^a,c   Smith, Scott A ^d   Crowe, James E ^d,e   Doranz, Benjamin J ^f   Kahle, Kristen M ^f   Pfaff, Jennifer M ^f   White, Laura J ^g   Sariol, Carlos A ^h,i   De Silva, Aravinda M ^b   Baric, Ralph S ^b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f Integral Molecular Inc   (United States)

^g Global Vaccines Inc   (United States)

^h UNIVERSITY OF PUERTO RICO   (Puerto Rico)

ⁱ UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Infectious clone; Neutralizing antibody

Indexed keywords

ANTISERUM; DENGUE VACCINE; GLYCOPROTEIN; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 3; DENGUE VIRUS 4; HINGE REGION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RHESUS MONKEY; SEROTYPE; VIRUS IMMUNITY; VIRUS RECOMBINANT;

INFECTIOUS CLONE; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE; DENGUE VIRUS; HEK293 CELLS; HUMANS; IMMUNITY; K562 CELLS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SEROTYPING; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; VIRAL ENVELOPE PROTEINS; VIREMIA;

EID: 84893458681     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1506982112     Document Type: Erratum

References (33)

1. Bhatt S, et al. (2013) The global distribution and burden of dengue. Nature 496(7446): 504-507.
2. World Health Organization (2009) Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control (World Health Organization, Geneva).
3. Sabchareon A, et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 380(9853):1559-1567.
4. Rothman AL (2011) Immunity to dengue virus: A tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11(8):532-543.
5. Dowd KA, Pierson TC (2011) Antibody-mediated neutralization of flaviviruses: A reductionist view. Virology 411(2):306-315.
6. Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 100(12):6986-6991.
7. Zhang Y, et al. (2004) Conformational changes of the flavivirus E glycoprotein. Structure 12(9):1607-1618.
8. de Alwis R, et al. (2012) Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 109(19):7439-7444.
9. Teoh EP, et al. (2012) The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 4(139):139ra83.
10. Smith SA, et al. (2012) Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 86(5): 2665-2675.
11. Modis Y, Ogata S, Clements D, Harrison SC (2005) Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79(2): 1223-1231.
12. Messer WB, et al. (2012) Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. PLoS Negl Trop Dis 6(2):e1486.
13. Modis Y, Ogata S, Clements D, Harrison SC (2004) Structure of the dengue virus envelope protein after membrane fusion. Nature 427(6972):313-319.
14. White LJ, et al. (2013) An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. J Virol 87(6):3409-3424.
15. Halstead SB, Chow JS, Marchette NJ (1973) Immunological enhancement of dengue virus replication. Nat New Biol 243(122):24-26.
16. Halstead SB (1988) Pathogenesis of dengue: Challenges to molecular biology. Science 239(4839):476-481.
17. Smith SA, et al. (2013) Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis 207(12):1898-1908.
18. Halstead SB, Casals J, Shotwell H, Palumbo N (1973) Studies on the immunization of monkeys against dengue. I. protection derived from single and sequential virus infections. Am J Trop Med Hyg 22(3):365-374.
19. Koraka P, Benton S, van Amerongen G, Stittelaar KJ, Osterhaus AD (2007) Characterization of humoral and cellular immune responses in cynomolgus macaques upon primary and subsequent heterologous infections with dengue viruses. Microbes Infect 9(8):940-946.
20. Kaufmann B, et al. (2010) Neutralization of west nile virus by cross-linking of its surface proteins with fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci USA 107(44):18950-18955.
21. Vogt MR, et al. (2009) Human monoclonal antibodies against west nile virus induced by natural infection neutralize at a postattachment step. J Virol 83(13):6494-6507.
22. Weiskopf D, et al. (2013) Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA 110(22):E2046-E2053.
23. Durbin AP, Whitehead SS (2011) Next-generation dengue vaccines: Novel strategies currently under development. Viruses 3(10):1800-1814.
24. Keck ZY, et al. (2012) Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog 8(4):e1002653.
25. Tsibane T, et al. (2012) Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog 8(12):e1003067.
26. Julien JP, et al. (2013) Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci USA 110(11):4351-4356.
27. Christian EA, et al. (2013) Atomic-level functional model of dengue virus Envelope protein infectivity. Proc Natl Acad Sci USA 110(46):18662-18667.
28. Paes C, et al. (2013) Atomic-level mapping of antibody epitopes on a GPCR. JACS 131(20):6952-6954.
29. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM (2009) Dengue virus neutralization by human immune sera: Role of envelope protein domain IIIreactive antibody. Virology 392(1):103-113.
30. Kraus AA, MesserW, Haymore LB, de Silva AM(2007) Comparison of plaque-and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 45(11):3777-3780.
31. Durbin AP, et al. (2001) Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 65(5):405-413.
32. Chenna R, et al. (2003) Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 31(13):3497-3500.
33. Bond CS, Schuttelkopf AW (2009) ALINE: A WYSIWYG protein-sequence alignment editor for publication-quality alignments. Acta Crystallogr D Biol Crystallogr 65(Pt 5): 510-512.